Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer An-open Single-arm Multic-centers Ib/II Study.

Next Previous
X
Search
Trial Profile

Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer An-open Single-arm Multic-centers Ib/II Study.

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Irinotecan (Primary) ; Surufatinib (Primary) ; Granulocyte macrophage colony stimulating factor
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 04 Jun 2024 Updated efficacy and safety results (n=30) presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jun 2023 Results of Phase Ib (Enrollment opened in Nov 2021 and data cutoff in Dec 2022; n=12) assessing the efficacy and safety of surufatinib plus camrelizumab, irinotecan and GM-CSF in advanced colorectal cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 25 May 2023 According to a HUTCHMED media release, data from this study will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top